Podcast episode 86 (in German)
Resveratrol – rise and fall of a longevity star
September 24, 2026
In 2008 a pharmaceutical company paid 720 million dollars for the company behind resveratrol. A few years later the programs had been buried; the molecule is still on the shelf today. The episode tells what it failed on.
What it is about
The rise unfolded in three acts: the French paradox of the nineties, the discovery of sirtuins at MIT and the 2003 finding that resveratrol activates these enzymes. In 2006 came the Nature paper according to which resveratrol extends the lives of mice fed a high-fat diet, and in 2008 the purchase of Sirtris by GlaxoSmithKline for 720 million dollars. The fall came piece by piece: no effect in normally fed mice, a measurement artifact in the original sirtuin assays, discontinued programs and dozens of human studies without a consistent result. The episode uses this trajectory as a pattern against which today’s longevity candidates can be tested — and cleanly separates what exactly failed.
Key points
- In 2003 Sinclair’s work showed that resveratrol activates sirtuins; in 2006, in Nature, it extended the lives of mice fed a high-fat diet, while in normally fed animals the effect did not appear.
- In 2008 GlaxoSmithKline bought the company Sirtris for 720 million dollars; a few years later the programs were discontinued because of efficacy and side effects.
- The independent mouse program that made rapamycin big failed resveratrol — the same body had already rejected fisetin and Ca-AKG in the same week.
- Several research groups showed that the originally measured sirtuin activation was partly an artifact of the fluorescence assay; whether it occurs in living tissue is still disputed today.
- Dozens of randomized studies and several meta-analyses on blood pressure, blood sugar, blood lipids, inflammation and cognition together yield no consistent picture.
- Bioavailability is the central problem: the liver and gut convert the substance so quickly that after 1 hour almost none of the free compound is left in the blood.
- The episode gives human evidence 2 with a negative direction, plus safety 7, use 7 and hype 1 — a lot of small things simply does not add up to a lot.
Where the data stop
What is missing here is not the number of studies but their weight. The existing human studies are small, short and work with soft endpoints such as blood values and questionnaires. There has never been a large study with a hard endpoint, and the French paradox is now considered a statistical artifact. To reach the amounts used in the mouse experiments, you would have to drink hundreds of glasses of red wine a day anyway.
Individual niches are still being seriously investigated, such as bone density and vascular function after menopause, so far with isolated signals. The more bioavailable successor pterostilbene has only small studies without hard endpoints behind it, and a rise in LDL cholesterol is known as a side finding. Interactions with blood thinners are documented and should be clarified with a doctor. Sirtuins as a research field remain unaffected — what failed is the shortcut, not the biology.
Listen (in German)
Listen on Spotify Apple Podcasts Amazon Music
Published on September 24, 2026.
The topic in the database
- Polyphenol from grapes. The advertised longevity benefit could not be confirmed in humans; the available studies were predominantly negative.Resveratrol
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-06.